University of South Dakota Sanford School of Medicine, Sioux Falls, South Dakota.
S D Med. 2022 Oct;75(10):453-454.
The midline catheter has gained popularity in the critical care setting as an alternative route of infusion to central venous catheters in recent years. This shift in practice is secondary to their ability to remain in place for up to 28 days and emerging evidence of their ability to safely infuse high-risk medications including vasopressor medications. Midline catheters are peripheral venous catheters between 10 and 25 cm in length inserted into the basilic, brachial, and cephalic veins of the upper arm and terminate in the axillary vein. This study sought to further define the safety profile of midline catheters as a route of infusion of vasopressor medications in patients and observe for potential complications.
A retrospective chart review of patients receiving vasopressor medications through midline catheters in a 33-bed intensive care unit over a period of nine months was conducted utilizing the EPIC EMR. The study utilized a convenience sampling method to collect data regarding demographics, midline catheter insertion data, length of vasopressor infusion, and presence or absence of extravasation of vasopressor medications, and other complications during time of administration and the period following discontinuation of vasopressor medications.
203 patients with midline catheters met inclusion criteria for the study over the nine-month period. Data collection yielded a total of 7,058 hours of vasopressor administration through midline catheters among the cohort with an average of 32.2 hours per patient. Norepinephrine was the most common vasopressor infused through midline catheters accounting for 5,542.8 midline hours (78.5 percent). There was no evidence of extravasation of vasopressor medications for the duration during which vasopressor medications were administered. 14 patients (6.9 percent) experienced complications prompting removal of midline catheters between 38 hours and 10 days after pressor discontinuation.
Due to the low rates of extravasation in midline catheters found in this study, midline catheters may serve as viable alternatives to central venous catheters for the infusion of vasopressor medications and should be considered by practitioners as a route of infusion in critically ill patients. Due to the inherent risks and barriers associated with the insertion of central venous catheters, which may delay treatment in hemodynamically unstable patients, practitioners may consider midline catheter insertion a first line route of infusion with minimal risk of vasopressor medication extravasation.
近年来,中线导管作为中央静脉导管的替代输液途径,在重症监护环境中越来越受欢迎。这种实践的转变是由于它们能够留置长达 28 天,并且有越来越多的证据表明它们能够安全输注包括血管加压药物在内的高危药物。中线导管是长度为 10 至 25 厘米的外周静脉导管,插入上臂的贵要静脉、肱静脉和头静脉,终止于腋静脉。本研究旨在进一步确定中线导管作为血管加压药物输注途径的安全性概况,并观察潜在并发症。
对在九个月期间,33 张床的重症监护病房中接受通过中线导管输注血管加压药物的患者进行回顾性图表审查,使用 EPIC EMR。该研究采用便利抽样方法收集有关人口统计学、中线导管插入数据、血管加压药物输注时间、血管加压药物外渗以及给药期间和停止血管加压药物后期间存在的其他并发症的数据。
在九个月期间,有 203 名中线导管患者符合研究纳入标准。数据收集共产生了该队列中通过中线导管输注的总共 7058 小时的血管加压药物,每位患者平均输注 32.2 小时。去甲肾上腺素是通过中线导管输注的最常见的血管加压药物,占 5542.8 个中线小时(78.5%)。在输注血管加压药物期间,没有证据表明血管加压药物外渗。在停止升压药物后 38 小时至 10 天之间,有 14 名患者(6.9%)因并发症而需要移除中线导管。
由于本研究中线导管中发现的外渗率较低,中线导管可能作为血管加压药物输注的中央静脉导管的可行替代品,并且应被临床医生视为危重症患者的输注途径。由于中心静脉导管插入相关的固有风险和障碍可能会延迟血流动力学不稳定患者的治疗,因此临床医生可能会考虑将中线导管插入作为一种最小血管加压药物外渗风险的一线输注途径。